Significant Digits: Responsible use of quantitative information

We live in an age when good policies are assumed to be evidence-based. And that evidential base is assumed to be at its best when expressed in numbers. The digital information may be derived from quantitative data organised in statistics, or from qualitative data organised in indicators. Either way, evidence in digital form provides the accepted foundation of policy arguments over a very broad range of issues. In the policy realm there are frequent debates over particular policy issues and their associated evidence. But only rarely is the nature of the evidence called into question. Such a faith in numbers can be dangerous. Policies in economic and financial policy, based on numbers whose significance was less than assumed, recently turned out to be quite disastrously wrong. Other examples can easily be cited. The decades-long period of blaming dietary fats for heart disease, rather than sugar, is a notable recent case. We are concerned here with the systemic problem: whether we are regularly placing too much of an evidentiary burden on quantitative sciences whose strength and maturity are inherently inadequate. The harm that has been done to those sciences, as well as to the policy process, should be recognised. Only in that way can future errors be avoided.JRC.DDG.01-Econometrics and applied statistic

The Challenge of Resilience in a Globalised World

Resilience determines the capacity to successfully deal with difficult events and to adapt and overcome adversity. It creates stability in a changing world which in turn promotes job creation, economic growth and environmental sustainability. Resilience is a fundamental prerequisite for Europe as the largest integrated economic area in the world and has an important social dimension which requires the active cooperation of all stakeholders; citizens, the private sector, governments and NGOs included. This report discusses the concept of resilience from different perspectives and the role of science in the continuous process of building a resilient, stable, competitive and prosperous Europe.JRC.G-Institute for the Protection and Security of the Citizen (Ispra

ARTEFACTS: How do we want to deal with the future of our one and only planet?

The European Commission’s Science and Knowledge Service, the Joint Research Centre (JRC), decided to try working hand-in-hand with leading European science centres and museums. Behind this decision was the idea that the JRC could better support EU Institutions in engaging with the European public. The fact that European Union policies are firmly based on scientific evidence is a strong message which the JRC is uniquely able to illustrate. Such a collaboration would not only provide a platform to explain the benefits of EU policies to our daily lives but also provide an opportunity for European citizens to engage by taking a more active part in the EU policy making process for the future. A PILOT PROGRAMME To test the idea, the JRC launched an experimental programme to work with science museums: a perfect partner for three compelling reasons. Firstly, they attract a large and growing number of visitors. Leading science museums in Europe have typically 500 000 visitors per year. Furthermore, they are based in large European cities and attract local visitors as well as tourists from across Europe and beyond. The second reason for working with museums is that they have mastered the art of how to communicate key elements of sophisticated arguments across to the public and making complex topics of public interest readily accessible. That is a high-value added skill and a crucial part of the valorisation of public-funded research, never to be underestimated. Finally museums are, at present, undergoing something of a renaissance. Museums today are vibrant environments offering new techniques and technologies to both inform and entertain, and attract visitors of all demographics.JRC.H.2-Knowledge Management Methodologies, Communities and Disseminatio

Before AGI arrives : why 2025-2030 determines the future of democratic AI governance

Published online: July 2025This paper argues that democratic societies face a critical three- to five-year window (2025-2030) to establish effective governance of artificial intelligence before the potential emergence of Artificial General Intelligence (AGI). The analysis demonstrates that AI capabilities are advancing exponentially while democratic institutions respond at traditional policy speeds, creating a dangerous mismatch. Power is rapidly concentrating in private technology corporations that now control 85-90% of AI computational resources and talent, while public sector AI investment lags dramatically behind private funding. The paper outlines essential policy actions including governance innovation, strategic public investment of €5 billion annually, international coordination mechanisms, and proactive risk mitigation. Failure to act within this narrow window risks permanent democratic disempowerment, entrenched power asymmetries, and irreversible safety risks as AI systems potentially surpass human capabilities in critical governance domains

Preserving human agency in the age of AI

Published online: July 2025A mounting body of evidence shows artificial intelligence is fundamentally reshaping human experience, eroding essential capabilities, and threatening social cohesion. This policy brief synthesises key findings on the mounting crisis of human agency, documents concerning impacts already visible across society, and proposes a comprehensive framework for intervention. The evidence demonstrates a pattern of accelerating disconnection, skill erosion, and psychological strain that demands urgent action within a three- to five-year window before AI capabilities potentially reach levels that could permanently alter the human-technology relationship. Our approach emphasises the development of psycho-emotional resilience as the critical foundation for human flourishing in the AI age, complemented by supportive skill development and strengthened community structures

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

Pharmacotherapy of acute myeloid leukemia (AML) remains challenging, and the disease has one of the lowest curability rates among hematological malignancies. The therapy outcomes are often compromised by the existence of a resistant AML phenotype associated with overexpression of ABCB1 and ABCG2 transporters. Because AML induction therapy frequently consists of anthracycline-like drugs, their efficiency may also be diminished by drug biotransformation via carbonyl reducing enzymes (CRE). In this study, we investigated the modulatory potential of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib on AML resistance using peripheral blood mononuclear cells (PBMC) isolated from patients with de novo diagnosed AML. We first confirmed inhibitory effect of the tested drugs on ABCB1 and ABCG2 in ABC transporter-expressing resistant HL-60 cells while also showing the ability to sensitize the cells to cytotoxic drugs even as no effect on AML-relevant CRE isoforms was observed. All tested CDK4/6 inhibitors elevated mitoxantrone accumulations in CD34+ PBMC and enhanced accumulation of mitoxantrone was found with abemaciclib and ribociclib in PBMC of FLT3-ITD- patients. Importantly, the accumulation rate in the presence of CDK4/6 inhibitors positively correlated with ABCB1 expression in CD34+ patients and led to enhanced apoptosis of PBMC in contrast to CD34− samples. In summary, combination therapy involving CDK4/6 inhibitors could favorably target multidrug resistance, especially when personalized based on CD34− and ABCB1-related markers

Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors

Pharmacotherapy of acute myeloid leukemia (AML) remains challenging, and the disease has one of the lowest curability rates among hematological malignancies. The therapy outcomes are often compromised by the existence of a resistant AML phenotype associated with overexpression of ABCB1 and ABCG2 transporters. Because AML induction therapy frequently consists of anthracycline-like drugs, their efficiency may also be diminished by drug biotransformation via carbonyl reducing enzymes (CRE). In this study, we investigated the modulatory potential of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib on AML resistance using peripheral blood mononuclear cells (PBMC) isolated from patients with de novo diagnosed AML. We first confirmed inhibitory effect of the tested drugs on ABCB1 and ABCG2 in ABC transporter-expressing resistant HL-60 cells while also showing the ability to sensitize the cells to cytotoxic drugs even as no effect on AML-relevant CRE isoforms was observed. All tested CDK4/6 inhibitors elevated mitoxantrone accumulations in CD34+ PBMC and enhanced accumulation of mitoxantrone was found with abemaciclib and ribociclib in PBMC of FLT3-ITD- patients. Importantly, the accumulation rate in the presence of CDK4/6 inhibitors positively correlated with ABCB1 expression in CD34+ patients and led to enhanced apoptosis of PBMC in contrast to CD34− samples. In summary, combination therapy involving CDK4/6 inhibitors could favorably target multidrug resistance, especially when personalized based on CD34− and ABCB1-related markers.</jats:p

RESONANCES I: FOOD

The book, an art book on food, is based on material gathered during RESONANCES I, an ad hoc project organized by the Joint Research Centre of the European Commisison at the occasion of the Universal Exhibition EXPO 2015: Feeding the Planet, Energy for Life.The material has been deconstructed and reconstructed into a new narrative that evokes the transition of considering food as a mere scientific, technical and commercial matter of fact to food seen as a social cultural and political matter of concern.JRC.A.5 - Scientific Developmen